Seattle Genetics (SGEN) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Seattle Genetics Reports First Quarter 2017 Financial Results
April 27, 2017 4:02 PM EDT-First Quarter 2017 Revenues Were $109.1 Million, Including $70.3 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-Top-Line Data from ADCETRIS Phase 3 ECHELON-1 Trial Expected in 2017-
-ADCETRIS Supplemental Biologics License Application for Cutaneous T-Cell Lymphoma Planned in Mid-2017-
-Regulatory Discussions Support Planned Pivotal Trial of Enfortumab Vedotin (ASG-22ME) in Metastatic Urothelial Cancer-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)--... More
